Analyn Talip, MD
Endocrinology, Diabetes & Metabolism · West Columbia, SCNPI 1831196260
Payments from drug & device makers
Across 422 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Amgen$580
- Insulet Corporation$563
- Corcept Therapeutics$531
- Novo Nordisk$455
- AstraZeneca$438
- plus $5K from 44 others
Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$50
What the payments were for
- Food & beverage$8,747100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,763 in reported general payments places this provider in the 60th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 14 | $1,077,649 |
| OzempicSemaglutide | 263 | $413,533 |
| KorlymMifepristone | 16 | $384,509 |
| MounjaroTirzepatide | 117 | $180,649 |
| JardianceEmpagliflozin | 150 | $157,242 |
| TrulicityDulaglutide | 69 | $111,837 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 94 | $111,653 |
| FarxigaDapagliflozin Propanediol | 85 | $101,552 |
| Tresiba Flextouch U-100Insulin Degludec | 90 | $78,253 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $63,124 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $53,497 |
| Novolog FlexpenInsulin Aspart | 75 | $27,924 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 113 | $25,916 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $25,428 |
| Humalog Kwikpen U-100Insulin Lispro | 64 | $23,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Farxiga | $438 | $1,179,20199 claims |
| Novo NordiskOzempic, Novolog | $455 | $421,339288 claims |
| Corcept TherapeuticsKorlym | $531 | $384,50916 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,045 | $306,962235 claims |
| Boehringer IngelheimJardiance | $175 | $157,242150 claims |
| MerckJanuvia, Janumet Xr | $53 | $33,03541 claims |
| AbbVieSynthroid | $220 | $9,402113 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $152 | $7,727613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in West Columbia
- Frank FerraroWest Columbia$10K
- Swathi BeeravoluWest Columbia$9K
- Gayatri KuragantiWest Columbia$9K
- Ronald MayfieldSpartanburg$8.9M
- Donald EagertonMyrtle Beach$7.9M
- Beatrice HullCharleston$987K
- Anne LarochelleMyrtle Beach$678K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.